Home > Research > Publications & Outputs > Barriers to access to opioid medicines

Research

Associated organisational unit

Electronic data

  • Vranken Barriers to access to opioid medicines_resubmission2908_clean

    Rights statement: This is the author’s version of a work that was accepted for publication in The Lancet Oncology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in The Lancet Oncology, 17, 1, 2016 DOI: 10.1016/S1470-2045(15)00365-4

    Accepted author manuscript, 477 KB, PDF document

    Available under license: CC BY-NC-ND: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Links

Text available via DOI:

View graph of relations

Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries. / Vranken, Marjolein J. M.; Lisman, John A.; Mantel-Teeuwisse, Aukje K et al.
In: Lancet Oncology, Vol. 17, No. 1, 01.2016, p. e13-e22.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Vranken, MJM, Lisman, JA, Mantel-Teeuwisse, AK, Jünger, S, Scholten, W, Radbruch, L, Payne, SA & Schutjens, M-HDB 2016, 'Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries', Lancet Oncology, vol. 17, no. 1, pp. e13-e22. https://doi.org/10.1016/S1470-2045(15)00365-4

APA

Vranken, M. J. M., Lisman, J. A., Mantel-Teeuwisse, A. K., Jünger, S., Scholten, W., Radbruch, L., Payne, S. A., & Schutjens, M-H. D. B. (2016). Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries. Lancet Oncology, 17(1), e13-e22. https://doi.org/10.1016/S1470-2045(15)00365-4

Vancouver

Vranken MJM, Lisman JA, Mantel-Teeuwisse AK, Jünger S, Scholten W, Radbruch L et al. Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries. Lancet Oncology. 2016 Jan;17(1):e13-e22. Epub 2015 Dec 23. doi: 10.1016/S1470-2045(15)00365-4

Author

Vranken, Marjolein J. M. ; Lisman, John A. ; Mantel-Teeuwisse, Aukje K et al. / Barriers to access to opioid medicines : a review of national legislation and regulations of 11 central and eastern European countries. In: Lancet Oncology. 2016 ; Vol. 17, No. 1. pp. e13-e22.

Bibtex

@article{863e9ff872cc4d58a36b6bce1bb1a6fc,
title = "Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries",
abstract = "Control measures designed to prevent the misuse of opioid medicines can often unintentionally restrict legitimate medical use, leaving patients with cancer in pain. This study aimed to develop and validate an assessment instrument based on WHO policy guidelines to systematically identify legal and regulatory barriers to opioid access in 11 European countries (Bulgaria, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Serbia, Slovakia, Slovenia, and Turkey) as part of the Access to Opioid Medication in Europe project. Relevant legislation and regulations were independently assessed by three reviewers and potential barriers were identified within nine categories including prescribing, penalties, and others. Potential barriers were identified in all countries, ranging from 22 potential barriers (Cyprus) to 128 potential barriers (Lithuania). The total number of barriers in a single category varied from one (Slovenia, usage category) to 49 (Greece, prescribing category). Differences, such as prescription validity, varied within one category, ranging from 5 days (Hungary) to 13 weeks (Cyprus). The results of this Review should give rise to a national review and revision of provisions that impede access to opioids, disproportionate to their (intended) benefit in preventing misuse, in these 11 European countries.",
author = "Vranken, {Marjolein J. M.} and Lisman, {John A.} and Mantel-Teeuwisse, {Aukje K} and Saskia J{\"u}nger and Willem Scholten and Lukas Radbruch and Payne, {Sheila Alison} and Schutjens, {Marie-H{\'e}l{\`e}ne D. B.}",
note = "This is the author{\textquoteright}s version of a work that was accepted for publication in The Lancet Oncology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in The Lancet Oncology, 17, 1, 2016 DOI: 10.1016/S1470-2045(15)00365-4",
year = "2016",
month = jan,
doi = "10.1016/S1470-2045(15)00365-4",
language = "English",
volume = "17",
pages = "e13--e22",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Barriers to access to opioid medicines

T2 - a review of national legislation and regulations of 11 central and eastern European countries

AU - Vranken, Marjolein J. M.

AU - Lisman, John A.

AU - Mantel-Teeuwisse, Aukje K

AU - Jünger, Saskia

AU - Scholten, Willem

AU - Radbruch, Lukas

AU - Payne, Sheila Alison

AU - Schutjens, Marie-Hélène D. B.

N1 - This is the author’s version of a work that was accepted for publication in The Lancet Oncology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in The Lancet Oncology, 17, 1, 2016 DOI: 10.1016/S1470-2045(15)00365-4

PY - 2016/1

Y1 - 2016/1

N2 - Control measures designed to prevent the misuse of opioid medicines can often unintentionally restrict legitimate medical use, leaving patients with cancer in pain. This study aimed to develop and validate an assessment instrument based on WHO policy guidelines to systematically identify legal and regulatory barriers to opioid access in 11 European countries (Bulgaria, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Serbia, Slovakia, Slovenia, and Turkey) as part of the Access to Opioid Medication in Europe project. Relevant legislation and regulations were independently assessed by three reviewers and potential barriers were identified within nine categories including prescribing, penalties, and others. Potential barriers were identified in all countries, ranging from 22 potential barriers (Cyprus) to 128 potential barriers (Lithuania). The total number of barriers in a single category varied from one (Slovenia, usage category) to 49 (Greece, prescribing category). Differences, such as prescription validity, varied within one category, ranging from 5 days (Hungary) to 13 weeks (Cyprus). The results of this Review should give rise to a national review and revision of provisions that impede access to opioids, disproportionate to their (intended) benefit in preventing misuse, in these 11 European countries.

AB - Control measures designed to prevent the misuse of opioid medicines can often unintentionally restrict legitimate medical use, leaving patients with cancer in pain. This study aimed to develop and validate an assessment instrument based on WHO policy guidelines to systematically identify legal and regulatory barriers to opioid access in 11 European countries (Bulgaria, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Serbia, Slovakia, Slovenia, and Turkey) as part of the Access to Opioid Medication in Europe project. Relevant legislation and regulations were independently assessed by three reviewers and potential barriers were identified within nine categories including prescribing, penalties, and others. Potential barriers were identified in all countries, ranging from 22 potential barriers (Cyprus) to 128 potential barriers (Lithuania). The total number of barriers in a single category varied from one (Slovenia, usage category) to 49 (Greece, prescribing category). Differences, such as prescription validity, varied within one category, ranging from 5 days (Hungary) to 13 weeks (Cyprus). The results of this Review should give rise to a national review and revision of provisions that impede access to opioids, disproportionate to their (intended) benefit in preventing misuse, in these 11 European countries.

U2 - 10.1016/S1470-2045(15)00365-4

DO - 10.1016/S1470-2045(15)00365-4

M3 - Journal article

VL - 17

SP - e13-e22

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 1

ER -